TY - JOUR
T1 - The central biobank and virtual biobank of BiOMarKaPD: a resource for studies on neurodegenerative diseases
AU - Reijs, Babette L. R.
AU - Teunissen, Charlotte E.
AU - Goncharenko, Nikolai
AU - Betsou, Fay
AU - Blennow, Kaj
AU - Baldeiras, Ines
AU - Brosseron, Frederic
AU - Cavedo, Enrica
AU - Fladby, Tormod
AU - Froelich, Lutz
AU - Gabryelewicz, Tomasz
AU - Gurvit, Hakan
AU - Kapaki, Elisabeth
AU - Koson, Peter
AU - Kulic, Luka
AU - Lehmann, Sylvain
AU - Lewczuk, Piotr
AU - Lleo, Alberto
AU - Maetzler, Walter
AU - de Mendonca, Alexandre
AU - Miller, Anne-Marie
AU - Molinuevo, Jose L.
AU - Mollenhauer, Brit
AU - Parnetti, Lucilla
AU - Rot, Uros
AU - Schneider, Anja
AU - Simonsen, Anja Hviid
AU - Tagliavini, Fabrizio
AU - Tsolaki, Magda
AU - Verbeek, Marcel M.
AU - Verhey, Frans R. J.
AU - Zboch, Marzena
AU - Winblad, Bengt
AU - Scheltens, Philip
AU - Zetterberg, Henrik
AU - Visser, Pieter Jelle
PY - 2015/10/15
Y1 - 2015/10/15
N2 - Biobanks are important resources for biomarker discovery and assay development. Biomarkers for Alzheimer's and Parkinson's disease (BIOMARKAPD) is a European multi-center study, funded by the EU Joint Programme-Neurodegenerative Disease Research, which aims to improve the clinical use of body fluid markers for the diagnosis and prognosis of Alzheimer's disease (AD) and Parkinson's disease (PD). The objective was to standardize the assessment of existing assays and to validate novel fluid biomarkers for AD and PD. To support the validation of novel biomarkers and assays, a central and a virtual biobank for body fluids and associated data from subjects with neurodegenerative diseases have been established. In the central biobank, cerebrospinal fluid (CSF) and blood samples were collected according to the BIOMARKAPD standardized pre-analytical procedures and stored at Integrated BioBank of Luxembourg. The virtual biobank provides an overview of available CSF, plasma, serum, and DNA samples at each site. Currently, at the central biobank of BIOMARKAPD samples are available from over 400 subjects with normal cognition, mild cognitive impairment (MCI), AD, frontotemporal dementia (FTD), vascular dementia, multiple system atrophy, progressive supranuclear palsy, PD, PD with dementia, and dementia with Lewy bodies. The virtual biobank contains information on over 8,600 subjects with varying diagnoses from 21 local biobanks. A website has been launched to enable sample requests from the central biobank and virtual biobank.
AB - Biobanks are important resources for biomarker discovery and assay development. Biomarkers for Alzheimer's and Parkinson's disease (BIOMARKAPD) is a European multi-center study, funded by the EU Joint Programme-Neurodegenerative Disease Research, which aims to improve the clinical use of body fluid markers for the diagnosis and prognosis of Alzheimer's disease (AD) and Parkinson's disease (PD). The objective was to standardize the assessment of existing assays and to validate novel fluid biomarkers for AD and PD. To support the validation of novel biomarkers and assays, a central and a virtual biobank for body fluids and associated data from subjects with neurodegenerative diseases have been established. In the central biobank, cerebrospinal fluid (CSF) and blood samples were collected according to the BIOMARKAPD standardized pre-analytical procedures and stored at Integrated BioBank of Luxembourg. The virtual biobank provides an overview of available CSF, plasma, serum, and DNA samples at each site. Currently, at the central biobank of BIOMARKAPD samples are available from over 400 subjects with normal cognition, mild cognitive impairment (MCI), AD, frontotemporal dementia (FTD), vascular dementia, multiple system atrophy, progressive supranuclear palsy, PD, PD with dementia, and dementia with Lewy bodies. The virtual biobank contains information on over 8,600 subjects with varying diagnoses from 21 local biobanks. A website has been launched to enable sample requests from the central biobank and virtual biobank.
KW - biobank
KW - cerebrospinal fluid
KW - dementia
KW - Alzheimer's disease
KW - Parkinson's disease
KW - neurodegenerative disorders
KW - body fluids
U2 - 10.3389/fneur.2015.00216
DO - 10.3389/fneur.2015.00216
M3 - Article
C2 - 26528237
SN - 1664-2295
VL - 6
JO - Frontiers in Neurology
JF - Frontiers in Neurology
IS - OCT
M1 - 216
ER -